###begin article-title 0
Regulation of Annexin I in Rheumatoid Synovial Cells by Glucocorticoids and Interleukin-1
###end article-title 0
###begin p 1
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
The glucocorticoid (GC)-induced antiinflammatory molecule annexin I is expressed in leukocytes and has antiinflammatory effects in animal models of arthritis, but the expression of annexin I in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) is unknown. We report the constitutive and dexamethasone (DEX)-inducible expression of annexin I in RA FLS. DEX increased FLS annexin I protein translocation and mRNA expression. Interleukin (IL)-1beta also induced annexin I translocation and mRNA but also increased intracellular protein. DEX and IL-1 had additive effects on annexin I mRNA, but DEX inhibited the inducing effect of IL-1beta on cell surface annexin I. These results indicate that glucocorticoids and IL-1beta upregulate the synthesis and translocation of annexin I in RA FLS, but interdependent signalling pathways are involved.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 171 172 171 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 51 56 <span type="species:ncbi:9606">human</span>
Glucocorticoids have been used in the treatment of human rheumatoid arthritis (RA) for fifty years see [1], but their mechanisms of action remain incompletely understood [2].
###end p 4
###begin p 5
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 352 353 352 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 288 299 <span type="species:ncbi:9606">participant</span>
Glucocorticoids induce the synthesis and cell surface translocation of annexin I (also known as lipocortin 1), a 37 kD member of the annexin superfamily of calcium and phospholipid binding proteins [3-5]. Antagonism of annexin I worsens inflammation [6-10], suggesting annexin I is a key participant in the antiinflammatory actions of glucocorticoids [2, 11].
###end p 5
###begin p 6
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 208 209 208 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 211 212 211 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 328 333 <span type="species:ncbi:9606">human</span>
Annexin I has been demonstrated in human blood leukocytes and RA tissue [12, 13]. It exerts a constitutive inhibitory influence, and mediates the inhibitor effects of glucocorticoids, in rodent models of RA [3, 9, 10, 14-16]. Regulated expression of functionally active cell surface annexin I binding sites has been reported in human RA fibroblast-like synoviocytes (FLS) [17, 18]. Despite this, the expression and regulation of annexin I in FLS has not been reported. The present study was designed to examine the expression of annexin I in RA FLS, and to examine the regulation of FLS annexin I by glucocorticoids and interleukin (IL)-1beta.
###end p 6
###begin title 7
MATERIALS AND METHODS
###end title 7
###begin title 8
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human synovial fibroblast culture
###end title 8
###begin p 9
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 536 538 536 538 <chem-struct xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ca</chem-struct>
###xml 545 547 545 547 <chem-struct xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mg</chem-struct>
###xml 716 717 710 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 720 721 714 715 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 793 794 781 782 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 791 794 779 782 <chem-struct xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CO<sub>2</sub></chem-struct>
###xml 860 861 848 849 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1087 1089 1075 1077 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 1092 1094 1080 1082 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
All patients met American College of Rheumatology criteria for the classification of RA [19]. Cultured FLS were grown from synovial specimens surgically excised from knee, hip, and shoulder joints of patients with RA, as described in [20]. Briefly, synovial fragments (2-3 mm) were placed into 50 mL (per 2g) of enzyme solution containing 1 mg/mL Dispase (0.5 U/mg, Boehringer Mannheim, Sydney, Australia), 1 mg/mL collagenase (type II, 1 /mg; Sigma, St Louis, Mich), and 1 mg/mL DNase type I. (2, 000 units/mL; Boehringer Mannheim) in Ca++ and Mg++ free Hanks' balanced salt solution (HBSS, ICN Laboratories, UK) stirred for 1 hour at 37degreesC. The digests were filtered and washed. Cells at a concentration of 106-107 /mL were placed in fresh RPMI/10% FCS and cultured at 37degreesC, 5% CO2. At the third passage, cells were frozen in liquid nitrogen at 106 /mL in RPMI/20%FCS containing 10% dimethylsulfoxide (Ajax Chemicals, Sydney, Australia). Thawed cells were used in experiments between passages 5-8. Cells were cultured in RPMI/10% FCS and treated with dexamethasone (DEX) (10-8-10-7 M) and/or IL-1beta (1 ng/mL) for up to 24 hours.
###end p 9
###begin title 10
Analysis of cell surface annexin I
###end title 10
###begin p 11
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 149 150 149 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 515 518 514 517 <chem-struct xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HCL</chem-struct>
###xml 738 744 <span type="species:ncbi:9986">rabbit</span>
Cell surface annexin I was obtained by washing cell monolayers with PBS containing 10 mM EDTA, as described in [14]. Briefly, cell monolayers at 2x105 /mL were washed with PBS and then with PBS containing 10 mM EDTA for 3-5 minutes at room temperature. Total protein was concentrated 10-fold by centrifuge cryo-evaporation (Jouan, St Nazaire, France), and resuspended in 20 mul of PBS for subsequent Western blotting with a specific antihuman annexin I monoclonal antibody (mAb). Proteins were isolated by 12% Tris-HCL gel and transferred onto nitrocellulose membrane. The nitrocellulose was blocked for 1 hour in 5% skim milk in Tris buffer. The membrane was subsequently incubated with 1 mug/mL of anti-annexin I mAb and HRP-conjugated rabbit antimouse IgG (diluted 1 : 3000). The blot was finally developed using a chemiluminescence system (ECL). The molecular masses of the annexin I-positive immunoreactive bands were determined by comparison with the migration of molecular mass standards. Recombinant annexin I was a generous gift from Dr Y Giga-Hama, Osaka, Japan, and was assessed as a standard. Differences in blot density were confirmed using NIH Image (Bethesda, Md).
###end p 11
###begin title 12
Flow cytometric detection of annexin I
###end title 12
###begin p 13
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 28 33 <span type="species:ncbi:9606">human</span>
###xml 182 186 <span type="species:ncbi:307630">Colo</span>
###xml 407 412 <span type="species:ncbi:9940">sheep</span>
Intracellular expression of human synovial fibroblast annexin I was detected using permeabilization flow cytometry using a Cytomation MoFlo flow cytometer (Cytomation, Fort Collins, Colo, USA), as described in [21]. Briefly, cells were fixed and permeabilized by suspension in 2% paraformaldehyde and 0.2% saponin (Sigma)/PBS, then incubated sequentially with annexin I (or control) mAb and FITC-conjugated sheep antimouse IgG. Results are expressed as mean fluorescence intensity (MFI) after subtraction of MFI obtained with isotype-control antibody labelled cells.
###end p 13
###begin title 14
RT-PCR
###end title 14
###begin p 15
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 82 87 <span type="species:ncbi:9606">human</span>
Reverse transcription of RNA was carried out as previously described in [10]. The human annexin I primers used were as follows: upstream primer (position 84-112 (28 bp): GTA TCA GAA TTC CTC AAG CAG GCC TGG T) and downstream primer (position 1082-1110 (28 bp): TCC TCC ACA AAG AGC CAC CAG GAT TTT C). Primers for the control gene GAPDH were: 5' CGT CTT CAC CAC CAT GGA GA 3' (forward); 5' CGG CCA TCA CGC CAC AGT TT 3' (reverse), yielding a PCR product of 300 bp. cDNA was amplified for 30 cycles using a DNA thermal cycler (Hybaid, Omnigene). Following PCR, the amplified products were analyzed on a 1.6% agarose gel containing ethidium bromide, with a size marker (123 bp ladder, Gibco BRL), and gel loading was normalized to GAPDH products. Differences in intensity of staining between treatment and control-derived RNA were confirmed with an image analyzing system (Kodak Digital EDAS).
###end p 15
###begin p 16
###xml 50 52 50 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 267 269 267 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 272 274 272 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 930 932 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
Competitive RT-PCR was performed as described in [10]. Briefly, PCR MIMICs were generated by two successive PCR amplifications according to the PCR MIMIC construction kit (Clontech Laboratories, Inc, Palo Alto, Calif). Four-fold dilutions of each PCR MIMIC between 10-1-10-2 attomole/mL were added to PCR amplification reactions containing a constant amount of the sample cDNA. The PCR amplification was performed in one cycle for 5 minutes at 95degreesC, and in 26 cycles for denaturing at 94degreesC for 45 seconds, annealing at 55degreesC for 45 seconds and extending at 72degreesC for 90 seconds. To determine the amount of the target mRNA, PCR products were separated on a 1.6% agarose gel, and the intensity of staining was analyzed using computerized scanner and image analysis software (NIH Image). The concentration of the target mRNA was derived from the zero intersect of the log ratio of target to mimic PCR products [10].
###end p 16
###begin title 17
Statistical analysis
###end title 17
###begin p 18
###xml 68 69 66 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 86 87 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 104 105 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The data are presented as mean +/- SEM and analyzed by Mann-Whitney U test or Student t test. Values of P < .05 were regarded as statistically significant. Group sizes referred to in the text refer to numbers of experiments; in each case each experiment was performed with cells from a different donor.
###end p 18
###begin title 19
RESULTS
###end title 19
###begin title 20
Effect of DEX on FLS annexin I
###end title 20
###begin p 21
###xml 175 183 175 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 263 271 263 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 423 424 423 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 456 457 452 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 540 541 532 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 547 548 539 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 557 565 549 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 705 713 697 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 969 971 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
To investigate the expression and regulation of annexin I in FLS, annexin I mRNA was measured using competitive RT-PCR. Annexin I mRNA was constitutively expressed in RA FLS (Figure 1). DEX induced increased annexin I mRNA in RA synovial fibroblasts at 24 hours (Figure 1). In contrast, intracellular annexin I was inhibited by DEX, exhibiting a trend towards a significant reduction after 3 hours exposure to DEX (MFI (x103) : 1.7 +/- 0.1 cf 1.5 +/- 0.2, P = .057) and a significant reduction at 24 hours (MFI: 1.8 +/- 0.3 cf 1.4 +/- 0.3, n = 6, P < .01) (Figure 2). In contrast to the reduction in intracellular annexin I protein, DEX treatment increased cell surface annexin I at 3 hours and 24 hours (Figure 3). These data suggest that DEX induces the translocation of intracellular annexin I to the cell surface, followed by increased expression of annexin I mRNA. A smaller 33 kD fragment, previously shown to be a glucocorticoid-inducible fragment of annexin I [14], was also shown to be increased by DEX.
###end p 21
###begin title 22
Effect of interleukin-1beta on FLS annexin I
###end title 22
###begin p 23
###xml 59 67 56 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 135 143 129 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 317 325 308 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 328 329 319 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Treatment with IL-1beta also increased FLS annexin I mRNA (Figure 4). IL-1beta treatment also increased RA FLS cell surface annexin I (Figure 5). In contrast to the effect of DEX, however, IL-1beta significantly increased intracellular annexin I protein as well as cell surface annexin I, in comparison with control (Figure 6) (P = .007).
###end p 23
###begin title 24
Interaction of DEX and IL-1beta on FLS annexin I
###end title 24
###begin p 25
###xml 352 360 340 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 498 506 483 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 789 790 768 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 799 807 778 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
To assess whether the effects of glucocorticoid and IL-1beta on FLS annexin I synthesis were additive, cells were co-treated with DEX and IL-1beta. Annexin I mRNA was markedly and dose-dependently increased by the combination of DEX and IL-1betas, with significantly greater annexin I expression observed when compared to either IL-1beta or DEX alone (Figure 4). Surprisingly, the addition of DEX to IL-1beta led to inhibition of cell surface annexin I compared to either alone or untreated cells (Figure 5). These results suggest that the effects of IL-1 on cell surface annexin I are inhibited by DEX, despite DEX being an inducer of cell surface annexin I in its own right. The addition of DEX to IL-1beta also led to reduced intracellular annexin I protein compared to IL-1beta alone (P < .05) (Figure 6), suggesting that increase in annexin I mRNA with combination of DEX and IL-1 was inhibited post-transcriptionally leading to increase in annexin I protein.
###end p 25
###begin title 26
DISCUSSION
###end title 26
###begin p 27
###xml 63 64 63 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 281 282 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 374 375 374 375 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 373 375 373 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E<sub>2</sub></italic>
###xml 391 393 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 668 670 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 859 861 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 953 955 949 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 957 959 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1037 1039 1033 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1041 1043 1037 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 233 236 <span type="species:ncbi:10116">rat</span>
###xml 562 566 <span type="species:ncbi:10090">mice</span>
###xml 899 904 <span type="species:ncbi:9606">human</span>
###xml 1153 1158 <span type="species:ncbi:9606">human</span>
The very broad range of antiinflammatory effects of annexin I [7, 14, 22-24] suggests its potential as an endogenous and glucocorticoids induced antiinflammatory regulator in a disease such as RA. Antagonism of annexin I exacerbates rat adjuvant and carrageenan-induced arthritis [9, 10], and in adjuvant arthritis, this is associated with increased synovial prostaglandin E2 and TNF-alpha [10]. Moreover, in both models, antagonism of annexin I prevents the effects of exogenous glucocorticoids. Recent studies demonstrated that disruption of the Anx-1 gene in mice exacerbated arthritis severity and proinflammatory cytokine expression in antigen-induced arthritis [16]. The absence of Anx-1 was also associated with insensitivity to the antiinflammatory effects of dexamethasone, indicating a major role for Anx-1 in the pathopharmacology of inflammation [16]. Annexin I has been demonstrated in human peripheral blood leukocytes and in RA synovium [12, 13], and annexin I cell surface binding sites have been demonstrated in RA FLS [17, 18]. Synovial fibroblasts are important contributors to the pathology of RA, but the regulation of annexin I in human synovial cells by pro- and antiinflammatory mediators has not been previously reported.
###end p 27
###begin p 28
In the current study, we demonstrate that RA FLS constitutively express annexin I. DEX induced annexin I mRNA, associated with a concomitant reduction in intracellular annexin I, and an increase in cell surface annexin I. The increased annexin I mRNA in cells treated with DEX suggests that the reduction in intracellular annexin I protein is not the result of reduced synthesis but rather of increased export to the cell surface. These data suggest that DEX first induces the translocation of pre-existing annexin I to the cell surface, followed by reconstitution via new mRNA expression.
###end p 28
###begin p 29
###xml 198 200 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 263 265 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 1541 1542 1517 1518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 2051 2056 <span type="species:ncbi:9606">human</span>
The current results also demonstrate that IL-1beta increases annexin I transcription, synthesis, and cell surface translocation in FLS. IL-1beta induces c-jun/fos AP-1 subunit activation in RA FLS [25], and as the annexin I promoter region contains an AP-1 site [26] this is likely to be involved in the response to IL-1beta. Induction of antiinflammatory proteins by pro-inflammatory stimuli such as IL-1 is not surprising, as many molecules such as IL-10 are inducible by pro-inflammatory cytokines and participate in the regulatory control of inflammation. Given the positive effects of both DEX and IL-1beta, we anticipated an interaction between these stimuli on FLS annexin I. The combination of DEX and IL-1beta additively induced annexin I mRNA consistent with additive effects on separate transcription factors. Surprisingly, however, the addition of DEX to IL-1 was associated with reductions in both intracellular and cell surface protein. Of note, IL-1beta treatment did not induce the cell surface expression of the smaller 33 kD annexin I fragment which was observed with DEX treatment. The discrepant effects of DEX and IL-1beta on FLS intracellular annexin I protein suggests that the synthesis and cell surface translocation of annexin I are differently regulated by these two stimuli. These findings are consistent with the existence of differential post-transcriptional effects of DEX and IL-1beta on annexin I synthesis. On the basis that the antiinflammatory effects of annexin I depend upon cell surface translocation [7], the prevention by IL-1beta of DEX-induced annexin I surface translocation is consistent with cytokine-dependent limitation of annexin I in the setting of inflammation. In RA synovium, IL-1beta is chronically overproduced, and thus the effect of physiological and pharmacological glucocorticoids on annexin I may be chronically and specifically inhibited. No data exists on the effects of specific IL-1 antagonism, for example, using recombinant IL-1RA products such as anakinra, on annexin I expression in human RA.
###end p 29
###begin p 30
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 311 313 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 575 577 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 680 682 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 684 686 681 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 688 690 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 774 776 771 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 565 573 <span type="species:ncbi:9606">patients</span>
###xml 670 678 <span type="species:ncbi:9606">patients</span>
###xml 728 732 <span type="species:ncbi:10090">mice</span>
Although GC are effective agents in the treatment of RA, a proportion of patients with RA and other inflammatory diseases are resistant to their therapeutic effects. GC sensitivity has been reported to be associated with reduced GC receptor nuclear translocation [27], increased expression of GC receptor beta [28]-migration inhibitory factor (Aeberli et al, FEBS Letters in press). Annexin I responses to GC may also potentially be associated with GC resistance. Certainly, leukocyte intracellular annexin I protein responses to glucocorticoids are impaired in RA patients [29], leukocytes and synovial fibroblast cell surface annexin I binding sites are reduced in RA patients [17, 18, 30], and sensitivity to GC in arthritic mice is impaired in the absence of annexin I [16]. Annexin I expression is possibly an index for recognition of GC resistance. Direct links between annexin I and the complicated molecular mechanisms of GC resistance remain to be further investigated.
###end p 30
###begin p 31
###xml 121 126 <span type="species:ncbi:9606">human</span>
In conclusion, glucocorticoids and IL-1beta each increases the expression and cell surface translocation of annexin I in human RA FLS. Discrepant effects of combined DEX and IL-1beta suggest post-transcriptional interactions. Further studies are required to define the mechanisms of cell surface translocation of annexin I, the signaling pathways involved in glucocorticoid and cytokine regulation of synoviocyte annexin I, and the mechanism(s) of antiinflammatory action of annexin I.
###end p 31
###begin title 32
CONCLUSION
###end title 32
###begin p 33
###xml 97 102 <span type="species:ncbi:9606">human</span>
Annexin I is an important antiinflammatory protein, shown here to be constitutively expressed in human RA synoviocytes. The upregulation of synoviocyte annexin I by DEX supports the hypothesis that annexin I is involved in the physiological and pharmacological effects of glucocorticoids in RA. The discrepant effects of IL-1beta in the presence and absence of DEX suggest differential regulation of annexin I transcription, synthesis, and translocation.
###end p 33
###begin article-title 34
Glucocorticosteroids in the management of rheumatoid arthritis
###end article-title 34
###begin article-title 35
Anti-inflammatory actions of glucocorticoids: molecular mechanisms
###end article-title 35
###begin article-title 36
Exacerbation of adjuvant arthritis by adrenalectomy is associated with reduced leukocyte lipocortin 1
###end article-title 36
###begin article-title 37
###xml 73 76 <span type="species:ncbi:10116">rat</span>
Glucocorticoids modulate the cellular disposition of lipocortin 1 in the rat brain in vivo and in vitro
###end article-title 37
###begin article-title 38
Glucocorticoid-induced annexin 1 secretion by monocytes and peritoneal leukocytes
###end article-title 38
###begin article-title 39
Modulation of IL-1-induced neutrophil migration by dexamethasone and lipocortin 1
###end article-title 39
###begin article-title 40
###xml 36 41 <span type="species:ncbi:9606">human</span>
Mobilizing lipocortin 1 in adherent human leukocytes downregulates their transmigration
###end article-title 40
###begin article-title 41
###xml 35 40 <span type="species:ncbi:10090">mouse</span>
Acute inflammatory response in the mouse: exacerbation by immunoneutralization of lipocortin 1
###end article-title 41
###begin article-title 42
Antiinflammatory effect of lipocortin 1 in experimental arthritis
###end article-title 42
###begin article-title 43
###xml 59 62 <span type="species:ncbi:10116">rat</span>
Inhibitory effect of annexin I on synovial inflammation in rat adjuvant arthritis
###end article-title 43
###begin article-title 44
Annexin 1 binds to U937 monocytic cells and inhibits their adhesion to microvascular endothelium: involvement of the alpha 4 beta 1 integrin
###end article-title 44
###begin article-title 45
###xml 43 48 <span type="species:ncbi:9606">human</span>
Detection of intracellular lipocortin 1 in human leukocyte subsets
###end article-title 45
###begin article-title 46
Differential distribution of annexins-I, -II, -IV, and -VI in synovium
###end article-title 46
###begin article-title 47
Glucocorticoid inhibition of adjuvant arthritis synovial macrophage nitric oxide production: role of lipocortin 1
###end article-title 47
###begin article-title 48
###xml 109 113 <span type="species:ncbi:10090">mice</span>
Reduction in arthritis severity and modulation of immune function in tissue factor cytoplasmic domain mutant mice
###end article-title 48
###begin article-title 49
Modulation of inflammation and response to dexamethasone by Annexin 1 in antigen-induced arthritis
###end article-title 49
###begin article-title 50
###xml 84 89 <span type="species:ncbi:9606">human</span>
Annexin I and dexamethasone effects on phospholipase and cyclooxygenase activity in human synoviocytes
###end article-title 50
###begin article-title 51
###xml 56 61 <span type="species:ncbi:9606">human</span>
Annexin I surface binding sites and their regulation on human fibroblast-like synoviocytes
###end article-title 51
###begin article-title 52
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
###end article-title 52
###begin article-title 53
Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids
###end article-title 53
###begin article-title 54
###xml 44 49 <span type="species:ncbi:9606">human</span>
Expression of intracellular lipocortin 1 in human peripheral blood leukocyte subsets
###end article-title 54
###begin article-title 55
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 67 72 <span type="species:ncbi:9606">human</span>
Human recombinant lipocortin 1 inhibits prostacyclin production by human umbilical artery in vitro
###end article-title 55
###begin article-title 56
###xml 87 90 <span type="species:ncbi:10116">rat</span>
Lipocortin-1 (annexin-1) suppresses activation of autoimmune T cell lines in the Lewis rat
###end article-title 56
###begin article-title 57
Annexin-I inhibits phospholipase A2 by specific interaction, not by substrate depletion
###end article-title 57
###begin article-title 58
###xml 171 177 <span type="species:ncbi:9986">rabbit</span>
Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts
###end article-title 58
###begin article-title 59
Studies on the structural properties of lipocortin-1 and the regulation of its synthesis by steroids
###end article-title 59
###begin article-title 60
Mitogen-activated protein kinase pathways: therapeutic targets in steroid resistance?
###end article-title 60
###begin article-title 61
###xml 2 7 <span type="species:ncbi:9606">human</span>
A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mRNA is associated with rheumatoid arthritis
###end article-title 61
###begin article-title 62
Impaired glucocorticoid induction of mononuclear leukocyte lipocortin-1 in rheumatoid arthritis
###end article-title 62
###begin article-title 63
Specific binding of lipocortin-1 (annexin I) to monocytes and neutrophils is decreased in rheumatoid arthritis
###end article-title 63
###begin title 64
Figures and Tables
###end title 64
###begin p 65
###xml 231 233 231 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 346 347 346 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 664 665 664 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 84 89 <span type="species:ncbi:9606">human</span>
DEX effects on RA synovial fibroblast annexin I mRNA. Panel (a): RNA extracted from human RA FLS was subjected to competitive RT-PCR with (lanes 2-6 and 8-12) or without (lanes 1 and 7) mimic. Lanes 1-6: control; lanes 7-12: DEX 10-7 M for 24 hours. Annexin I mRNA content was greater in DEX-treated than vehicle-treated cells. Representative of n = 4 separate experiments from 4 separate RA donors. Panel (b): the log of the ratios of the annexin I and mimic PCR product band intensities were graphed as a function of the log of the amount of mimic added to the reaction. Increased annexin I mRNA is seen in DEX-treated RA synovial fibroblasts. Representative of n = 4 separate experiments from 4 separate RA donors.
###end p 65
###begin p 66
###xml 271 273 269 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 371 372 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 380 381 378 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
DEX effects on RA synovial fibroblast intracellular annexin I. Annexin I protein was detected in cultured RA FLS by permeabilization flow cytometry and displayed as mean +/- SEM mean fluorescence intensity (MFI). Compared to control (open bars), cells treated with DEX 10-7 M (filled bars) exhibited reduced intracellular annexin I at 3 hours and 24 hours, respectively (n = 6). *P < .05.
###end p 66
###begin p 67
###xml 91 93 91 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 577 578 577 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
DEX effects on RA synovial fibroblast cell surface annexin I. RA FLS were exposed to DEX 10-7 M for 3 hours and 24 hours, respectively. Cell surface annexin I was detected by Western blotting. Lanes 1 and 2 show 3-hour control, and DEX-treated cell surface eluates, lanes 3 and 4 show 24-hour control, and DEX-treated cell surface eluates. A 37 kD band representing full-length annexin I was increased at 3 hours and increased further at 24 hours in DEX. A smaller 33 kD fragment of annexin I was also increased by DEX. Data presented are from one experiment representative of n = 4.
###end p 67
###begin p 68
###xml 117 119 111 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 122 124 116 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 271 273 265 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 291 293 285 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 351 353 339 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 385 387 370 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 569 570 548 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
IL-1beta and DEX effects on RA synovial fibroblast annexin I mRNA. RA FLS were exposed to IL-1beta 1 ng/mL and DEX 10-7-10-8 M for 24 hours and annexin I mRNA measured by semiquantitative RT-PCR. Upper bands: annexin I, lower bands: GAPDH. Lane 1: control; lane 2: DEX 10-7 M; lane 3: DEX 10-8 M; lane 4: IL-1beta 1 ng/mL; lane 5: IL-1beta plus DEX 10-7 M; lane 6: IL-1beta plus DEX 10-8 M. DEX and IL-1beta both induced annexin I mRNA. Co-treatment with DEX and IL-1beta had additive effects on annexin I mRNA. Data presented are from one experiment representative of n = 4.
###end p 68
###begin p 69
###xml 125 127 119 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 130 132 124 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 297 299 285 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 306 308 294 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 502 503 484 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
IL-1beta and DEX effects on RA synovial fibroblast cell surface annexin I. RA FLS were exposed to IL-1beta 1 ng/mL and DEX 10-7-10-8 M for 24 hours. Cell surface annexin I was detected by Western blotting. Lane 1 and 2 show control, and IL-1beta-treated cells, lane 3 and 4 show IL-1beta + DEX (10-7 and 10-8 M)-treated cells. Cell surface annexin I was increased by IL-1beta. Cotreatment with DEX and IL-1beta inhibited cell surface annexin I. Data presented are from one experiment representative of n = 3.
###end p 69
###begin p 70
###xml 169 171 163 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 366 367 355 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 398 400 387 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 470 471 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 480 481 461 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
IL-1beta and DEX effects on RA synovial fibroblast intracellular annexin I. RA FLS were cultured for 24 hours with interleukin-1beta (IL-1, 1 ng/mL), and/or DEX (DEX, 10-8 M). Annexin I protein was detected by permeabilization flow cytometry and displayed as mean +/- SEM mean fluorescence intensity (MFI). IL-1beta significantly increased intracellular annexin I (*P < .01). The addition of DEX 10-8 M prevented the effect of IL-1beta on intracellular annexin I (daggerP < .05) (n = 6).
###end p 70

